Oncternal Therapeutics Inc (ONCT) Stock Price, Quote, News and Overview
NASDAQ:ONCT - Nasdaq - US68236P2065 - Common Stock - Currency: USD
ONCT Quote, Performance and Key Statistics
0.5266
-0.17 (-24.11%)
The current stock price of ONCT is 0.5266 USD. In the past month the price decreased by -64.89%. In the past year, price decreased by -93.89%.
ONCT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.39 | 329.14B | ||
| AMGN | AMGEN INC | 14.17 | 150.99B | ||
| GILD | GILEAD SCIENCES INC | 13.33 | 128.61B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1702.9 | 126.96B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.2 | 65.88B | ||
| ARGX | ARGENX SE - ADR | 330.52 | 37.54B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.72B | ||
| ONC | BEIGENE LTD-ADR | N/A | 26.39B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.52B | ||
| NTRA | NATERA INC | N/A | 20.79B | ||
| BIIB | BIOGEN INC | 7.22 | 17.39B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.30B |
Related stock screener links
About ONCT
Company Profile
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Company Info
Oncternal Therapeutics Inc
12230 El Camino Real, Suite 230
San Diego CALIFORNIA 92130 US
CEO: James B. Breitmeyer
Employees: 27
Company Website: https://www.oncternal.com/
Investor Relations: https://investor.oncternal.com/
Phone: 18584341113
Oncternal Therapeutics Inc / ONCT FAQ
What is the stock price of Oncternal Therapeutics Inc today?
The current stock price of ONCT is 0.5266 USD. The price decreased by -24.11% in the last trading session.
What is the ticker symbol for Oncternal Therapeutics Inc stock?
The exchange symbol of Oncternal Therapeutics Inc is ONCT and it is listed on the Nasdaq exchange.
On which exchange is ONCT stock listed?
ONCT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for Oncternal Therapeutics Inc stock?
6 analysts have analysed ONCT and the average price target is 2.04 USD. This implies a price increase of 287.39% is expected in the next year compared to the current price of 0.5266. Check the Oncternal Therapeutics Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is Oncternal Therapeutics Inc worth?
Oncternal Therapeutics Inc (ONCT) has a market capitalization of 1.56M USD. This makes ONCT a Nano Cap stock.
How many employees does Oncternal Therapeutics Inc have?
Oncternal Therapeutics Inc (ONCT) currently has 27 employees.
Is Oncternal Therapeutics Inc (ONCT) expected to grow?
The Revenue of Oncternal Therapeutics Inc (ONCT) is expected to grow by 161.75% in the next year. Check the estimates tab for more information on the ONCT EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy Oncternal Therapeutics Inc (ONCT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ONCT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ONCT, evaluating the profitability, health, valuation and growth aspects
- Oncternal Therapeutics Inc (ONCT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- Oncternal Therapeutics Inc (ONCT) Sales and EPS estimates to see what analysts future expectations are.
- Oncternal Therapeutics Inc (ONCT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- Oncternal Therapeutics Inc (ONCT) Insider and Institutional Ownership to learn about the owners and their transactions.
- Oncternal Therapeutics Inc (ONCT) Stock Chart to make your own analysis
- Oncternal Therapeutics Inc (ONCT) Latest news and press-releases to stay up to date.
Does Oncternal Therapeutics Inc (ONCT) stock pay dividends?
ONCT does not pay a dividend.
What is the Price/Earnings (PE) ratio of Oncternal Therapeutics Inc (ONCT)?
Oncternal Therapeutics Inc (ONCT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.69).
ONCT Technical Analysis
ONCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONCT. ONCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ONCT Financial Highlights
Over the last trailing twelve months ONCT reported a non-GAAP Earnings per Share(EPS) of -11.69. The EPS increased by 18.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -221.62% | ||
| ROE | -377.95% | ||
| Debt/Equity | 0 |
ONCT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ONCT. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 10.27% and a revenue growth 161.75% for ONCT